Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada.

ABSTRACT:

Background

Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) were approved in Canada in 2013. By 2018, treatment restrictions had been lifted in all provinces, making DAAs universally accessible. Here, we aim to assess progress toward HCV elimination in the DAA era (2014-2022) within the Canadian Co-infection Cohort.

Methods

The CCC is a multisite open cohort of people living with HIV-HCV coinfection with cohort visits scheduled biannually. We calculated annual cure rates overall by province and key population: gay bisexual and other men who have sex with men, people who inject drugs, and Indigenous peoples.

Results

Among the 952 participants eligible for DAAs, 65% (n = 623) were cured and 3% (n = 26) achieved late clearance without treatment by the end of t

SUBMITTER: El Sheikh MZ 

PROVIDER: S-EPMC12269190 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature